By admin 
In a significant move to address the persistent challenges of pediatric oncology, CureSearch for Children’s Cancer has announced that Dr. Robbie Majzner of the Dana-Farber Cancer Institute is the recipient of the 2026 CureSearch Catapult Award. This $2 million investment, co-funded in partnership with the Jeff Gordon Children’s Foundation, is specifically earmarked to launch a Phase I clinical trial for a sophisticated, next-generation Chimeric Antigen Receptor (CAR) T-cell therapy. The trial targets children and young adults suffering from relapsed or refractory neuroblastoma, a patient population that currently faces a dearth of effective therapeutic options and a grim prognosis.
The Catapult Award represents a strategic intervention in the medical research pipeline, designed to bridge the "Valley of Death"—the notorious gap between successful laboratory discovery and the commencement of human clinical trials. By providing the necessary capital at this high-risk, high-reward juncture, CureSearch aims to accelerate the delivery of innovative treatments from the laboratory bench to the patient’s bedside, potentially altering the trajectory of pediatric cancer care.
The Clinical Challenge of High-Risk Neuroblastoma
Neuroblastoma is a complex cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It is the most frequent extracranial solid tumor diagnosed in childhood and is responsible for more than 10% of all pediatric cancer deaths. Despite significant advancements in multimodal therapy—which often includes high-dose chemotherapy, surgical resection, radiation, and stem cell transplants—the survival rates for high-risk neuroblastoma have remained stubbornly below 50% for several decades.
For those children who do achieve remission, the long-term cost of survival is often steep. The intensity of current standard-of-care treatments can lead to chronic health issues, including hearing loss, cardiac dysfunction, and secondary malignancies. When the disease relapses or proves refractory to initial treatment, the medical community currently has very few tools left to offer, making the development of targeted, less toxic immunotherapies a top priority in the field.
The Evolution of CAR T-Cell Therapy in Solid Tumors
CAR T-cell therapy has already revolutionized the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL). This approach involves extracting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them to express a Chimeric Antigen Receptor that can recognize specific proteins on the surface of cancer cells. Once re-infused into the patient, these modified cells seek out and destroy the tumor.
However, translating the success seen in blood cancers to solid tumors like neuroblastoma has proven extraordinarily difficult. Solid tumors present a hostile microenvironment that can suppress immune activity. Furthermore, many CAR T-cells suffer from a phenomenon known as "exhaustion." After an initial period of activity, the engineered cells lose their ability to divide and kill, effectively becoming dormant while the cancer continues to proliferate.
Technical Innovation: The ZAP70 Signaling Protein
Dr. Majzner’s research at Dana-Farber seeks to solve the exhaustion problem through advanced cellular engineering. The new therapy targets GD2, a sugar-fat molecule (ganglioside) that is overexpressed on the surface of nearly all neuroblastoma cells but has limited expression on healthy tissues, making it an ideal target for immunotherapy.
While previous GD2-targeted CAR T-cells showed early promise, they frequently failed due to poor persistence in the body. Dr. Majzner’s team has redesigned the internal architecture of the CAR by incorporating a novel signaling protein called ZAP70. In a natural immune response, ZAP70 plays a critical role in transmitting signals from the T-cell receptor to the rest of the cell, orchestrating a sustained attack. By integrating this protein directly into the CAR structure, the researchers aim to create a "fitter" T-cell that can remain active longer, resist the suppressive signals of the tumor environment, and maintain a sustained assault on the neuroblastoma.
Preclinical data supporting this trial have been compelling. In laboratory models, these redesigned CAR T-cells demonstrated significantly more potent anti-tumor activity and greater longevity compared to traditional GD2 CAR designs. Furthermore, the studies indicated a potentially improved safety profile, reducing the risk of "off-target" effects that can occur when the immune system is hyper-activated.
Strategic Funding and the "Catapult" Mission
The 2026 Catapult Award is a testament to the collaborative nature of modern pediatric cancer research. The $2 million grant is a joint effort between CureSearch and the Jeff Gordon Children’s Foundation, an organization founded by the four-time NASCAR Cup Series champion that has long been dedicated to improving outcomes for children with cancer.
The Catapult program is distinct in its focus on late-stage preclinical and early-stage clinical development. While federal funding through the National Cancer Institute (NCI) often supports basic science, and pharmaceutical companies focus on large-scale Phase III trials, the early Phase I and II trials for pediatric-specific drugs often lack sufficient funding. This is because the market for pediatric cancer drugs is smaller than that for adult cancers, often leading to a lack of commercial incentive for traditional drug developers.
"One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," stated Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Timeline and Implementation of the Phase I Trial
The funding will facilitate the launch of a Phase I clinical trial, which is the first step in testing the new therapy in humans. This stage of research is primarily focused on safety and determining the appropriate dosage. However, in the context of CAR T-cell trials, researchers also look for early signals of efficacy and "persistence"—how long the engineered cells remain detectable in the patient’s bloodstream.
The trial is expected to enroll children and young adults with relapsed or refractory neuroblastoma who have exhausted standard treatment options. Participants will undergo leukapheresis to collect their T-cells, which will then be shipped to a specialized manufacturing facility to be engineered with the ZAP70-augmented GD2 CAR. After the cells are grown to sufficient numbers, they will be infused back into the patients following a short course of "lymphodepleting" chemotherapy, which prepares the body to receive the new immune cells.
Dr. Majzner emphasized the urgency of the project, stating, "Current GD2 CAR T cells only work in patients with small amounts of disease. We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Broader Implications for Oncology
The success of Dr. Majzner’s trial could have implications far beyond neuroblastoma. GD2 is also expressed in other difficult-to-treat pediatric cancers, such as osteosarcoma (a bone cancer) and certain types of brain tumors, including Diffuse Intrinsic Pontine Glioma (DIPG). If the ZAP70 signaling architecture proves effective in sustaining T-cell activity against neuroblastoma, it could serve as a blueprint for treating a wide array of solid tumors in both children and adults.
Furthermore, the trial contributes to the growing body of knowledge regarding "synthetic biology" in medicine. By fine-tuning the internal signaling of immune cells, scientists are moving toward a future where treatments are not just chemical compounds, but "living drugs" that can adapt to the evolving nature of cancer.
Conclusion
The 2026 CureSearch Catapult Award marks a pivotal moment for Dana-Farber Cancer Institute and the broader pediatric oncology community. By addressing the fundamental biological barriers that have hindered CAR T-cell therapy in the past, Dr. Robbie Majzner and his team are opening a new door for children who have run out of options. As the Phase I trial moves forward, the medical community will be watching closely, hopeful that this $2 million investment will yield a breakthrough that transforms high-risk neuroblastoma from a devastating diagnosis into a manageable, and ultimately curable, condition. Through the continued support of organizations like CureSearch and the Jeff Gordon Children’s Foundation, the path from scientific discovery to life-saving treatment continues to grow shorter, offering renewed hope to families worldwide.
